Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Aug 6;20(4):3317–3325. doi: 10.3892/mmr.2019.10562

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Chen et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 4. — Effect of afatinib on the ERK-VEGF/MMP9 signaling pathway. (A) Western blot and (B) densitometry analysis of VEGF and MMP9 protein expression levels. (C) Western blot and (D) densitometry analysis of ERK and p-ERK levels. The ratio of p-ERK/total ERK was evaluated. n=3. *P<0.05 vs. corresponding control. EGFR, epidermal growth factor receptor; VEGF, vascular endothelial growth factor; MMP, matrix metalloproteinase; siCTR, scrambled siRNA; si-EGFR, siRNA targeting EGFR; siRNA, small interference RNA; EGFR-TKI, afatinib treatment; TKI, tyrosine-kinase inhibitor; p-, phosphorylated.